TMCnet News
World Toll Like Receptor 4 (CD284 or TLR4) Pipeline Review 2016 - Research and MarketsResearch and Markets has announced the addition of the "Toll Like Receptor 4 (CD284 or TLR4) - Pipeline Review, H1 2016" report to their offering. Toll Like Receptor 4 (CD284 or TLR4) pipeline Target (News - Alert) constitutes close to 36 molecules. Out of which approximately 32 molecules are developed by Companies and remaining by the Universities/Institutes. The author's latest report Toll Like Receptor 4 - Pipeline Review, H1 2016, outlays comprehensive information on the Toll Like Receptor 4 (CD284 or TLR4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. Toll Like Receptor 4 (CD284 or TLR4) Toll-like receptor 4 is a protein encoded by the TLR4 gene. This receptor is mostly expressed in placenta, and in myelomonocytic subpopulation of the leukocytes. It is involved in LPS-independent inflammatory responses triggered by free fatty acids, such as palmitate, and Ni2+. It responses are triggered by Ni2+ require non-conserved. In complex with TLR6 promotes sterile inflammation in monocytes in response to oxidized low-density lipoprotein (oxLDL). The molecules developed by Companies in Phase II, Phase I, Prelinical and Discovery stages are 7, 2, 19 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively. Furthermore, this report also reviews key players involved in Toll Like Receptor 4 (CD284 or TLR4) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Key Topics Covered:
For more information about this report visit http://www.researchandmarkets.com/research/545255/toll_like Related Topics: Immune Disorders Drugs
View source version on businesswire.com: http://www.businesswire.com/news/home/20160829005868/en/ |
